Alphabet (NASDAQ:GOOGL) reported quarterly earnings of $1.06 per share which missed the analyst consensus estimate of $1.27 by 16.54 percent. This is a 24.29 percent decrease over earnings of $1.40 per share from theAlphabet (NASDAQ:GOOGL) reported quarterly earnings of $1.06 per share which missed the analyst consensus estimate of $1.27 by 16.54 percent. This is a 24.29 percent decrease over earnings of $1.40 per share from the same period last year. The company reported quarterly sales of $69.09 billion which missed the analyst consensus estimate of $70.91 billion by 2.56 percent. This is a 6.10 percent increase over sales of $65.12 billion the same period last year.
Clinical Study On DMT Inhaled Product For Treatment-Resistant Depression Completes Dosing Stage
Biomind Labs Inc. (OTC: BMNDF), a life sciences company developing medicinal next-generation psychedelics, completed the dose administration of 30 healthy subjects within its Phase 2 clinical trial of DMT-based proprietary drug BMND01 for the Treatment-Resistant Depression (TDR) disorder.
